QURE — Uniqure NV
NASDAQ · Healthcare · Biotechnology
$47.86
-$0.82 (-1.68%)
Uniqure NV (QURE) is a biotechnology company listed on NASDAQ. It is led by Matthew Craig Kapusta CPA, based in Paasheuvelweg 25, Amsterdam, Netherlands, 1105 BP, with about 221 employees. uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Net income was -$80.5M. QURE currently screens at market cap $3.04B.
Use this QURE page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the QURE quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the QURE SEC filings page. Lician reads the product cache first so this HTML stays unique to Uniqure NV even when a live quote feed is slow.
About Uniqure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
QURE Key Statistics
Market Cap
$3.04B
Volume
476,459
Previous Close
$51.05
Day Range
$50.05 – $51.13
P/B Ratio
11.40
EPS
-$4.92
Revenue
$0.00
Net Income
-$239.56M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
221
QURE Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$239.56M | -$308.48M | -$126.79M | $329.59M |
| EPS (Diluted) | -$4.92 | -$6.47 | -$2.71 | $7.04 |
Total Assets
$556.54M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$158.93M
Operating Cash Flow
-$182.73M
Free Cash Flow
$0.00
Uniqure NV Company Information
- CEO & Executive Director
- Matthew Craig Kapusta CPA
- Headquarters
- Paasheuvelweg 25, Amsterdam, Netherlands, 1105 BP
- Website
- www.uniqure.com
- Phone
- 31 20 240 6000
- IPO / Founded
- 2007-06-20
- Sector
- Healthcare
- Industry
- Biotechnology